Endogenous angiogenesis inhibitors and their therapeutic implications

International Journal of Biochemistry and Cell Biology

Volumn 33, Issue 4, 2001, Pages 357-369

  Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Cancer therapy; Neovascularization; Proteolytic fragments

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOSTATIN; ANTITHROMBIN; BETA CHEMOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; GAMMA INTERFERON; INTERLEUKIN 12; MASPIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN; PROLACTIN; RECOMBINANT PROTEIN; RESTIN; RETINA S ANTIGEN; SERINE PROTEINASE INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TOXIN; TROPONIN I; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG MEGADOSE; ENDOTHELIUM CELL; GENE THERAPY; GROWTH INHIBITION; HALF LIFE TIME; HUMAN; METASTASIS; MOLECULE; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; GENE THERAPY; HYDROLYSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANIMALIA;

EID: 0035049240     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(01)00023-1     Document Type: Review

References (88)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Clinical applications of research on angiogenesis
3. Molecular and biological properties of vascular endothelial growth factor
4. Quantitative angiogenesis assays: Progress and problems
5. Angiogenesis in cancer, vascular, rheumatoid and other disease
6. Tumor angiogenesis: Therapeutic implications
7. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone
8. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
9. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
10. Identification of an inhibitor of neovascularization from cartilage
11. A metalloproteinase inhibitor as an inhibitor of neovascularization
12. Troponin I is present in human cartilage and inhibits angiogenesis
13. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
14. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
15. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
16. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
17. Therapeutic potentials of angiostatin in the treatment of cancer
18. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
19. Angiostatin induces and sustains dormancy of human primary tumors in mice
20. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
21. Angiogenesis inhibitors in clinical trials
22. Angiogenesis research: From laboratory to clinic
23. Antiangiogenesis gene therapy
24. Tumor growth and neovascularization: An experimental model using the rabbit cornea
25. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
26. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
27. Endogenous angiogenesis inhibitors: Angiostatin, endostatin, and other proteolytic fragments
28. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor
29. Isolations of a cartilage factor that inhibits tumor neovascularization
30. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans
31. Tissue inhibitors of metalloproteinases: Evolution, structure and function
32. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
33. Gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice
34. Human recombinant interferon alpha-2a inhibits angiogenesis of chick area vasculosa in shell-less culture
35. Inhibition of angiogenesis in vivo by interleukin 12
36. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
37. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
38. Identification of soluble forms of the fibroblast growth factor receptor in blood
39. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
40. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
41. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
42. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
43. Impaired endochondral ossification and angiogenesis, and early lethality in mice deficient in membrane type matrix metalloproteinase I (MT1-MMP)
44. Incipient angiogenesis [editorial; comment]
45. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
46. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
47. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
48. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin
49. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4
50. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth
51. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
52. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
53. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
54. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells
55. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
56. Angiostatin binds ATP synthase on the surface of human endothelial cells
57. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a
58. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
59. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor
60. The rationale and future potential of angiogenesis inhibitors in neoplasia
61. Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
62. Combined effects of angiostatin and ionizing radiation in antitumour therapy
63. Antiangiogenic gene therapy
64. Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein
65. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
66. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
67. Maspin is an angiogenesis inhibitor
68. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
69. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
70. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
71. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
72. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
73. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors
74. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
75. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
76. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
77. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
78. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
79. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
80. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
81. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein
82. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
83. Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo
84. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme
85. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
86. Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin
87. Anti-angiogenic cues from vascular basement membrane collagen
88. Two RGD-independent alpha vbeta 3 integrin binding sites on Tumstatin regulate distinct anti-tumor properties